Showing results (1011-1020 of 1,217) with videos related to
Sort By:
Pageof 122
Diabetic Medicine : a Journal of the British Diabetic Association|May 28, 2022
Hypo-METRICS: Hypoglycaemia-MEasurement, ThResholds and ImpaCtS-A multi-country clinical study to define the optimal threshold and duration of sensor-detected hypoglycaemia that impact the experience of hypoglycaemia, quality of life and health economic outcomes: The study protocolPatrick Divilly, Natalie Zaremba, Zeinab Mahmoudi, et al.The Journal of Allergy and Clinical Immunology|September 25, 2010
Factors predicting inhaled corticosteroid responsiveness in African American patients with asthmaWendy Gould, Edward L Peterson, Gloria Karungi, et al.Arthritis and Rheumatism|June 12, 1999
High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis: analysis of a two-year, double-blind, randomized, controlled clinical trialP J Clements, D E Furst, W K Wong, et al.Seminars in Arthritis and Rheumatism|February 24, 2004
High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial: lessons learnedPhilip J Clements, James R Seibold, Daniel E Furst, et al.Inflammatory Bowel Diseases|April 29, 2017
Anti-TNF Treatment for Extraintestinal Manifestations of Inflammatory Bowel Disease in the Swiss IBD Cohort StudyStephan R Vavricka, Martin Gubler, Claudine Gantenbein, et al.Nature Communications|October 13, 2021
Relationship of insect biomass and richness with land use along a climate gradientJohannes Uhler, Sarah Redlich, Jie Zhang, et al.Journal of Immunology (Baltimore, Md. : 1950)|October 3, 2020
IgA Triggers Cell Death of Neutrophils When Primed by Inflammatory MediatorsMarc Wehrli, Christoph Schneider, Fabiola Cortinas-Elizondo, et al.Annals of Internal Medicine|June 3, 2000
Recombinant human relaxin in the treatment of scleroderma. A randomized, double-blind, placebo-controlled trialJ R Seibold, J H Korn, R Simms, et al.Arthritis and Rheumatism|December 30, 2006
Recombinant human anti-transforming growth factor beta1 antibody therapy in systemic sclerosis: a multicenter, randomized, placebo-controlled phase I/II trial of CAT-192Christopher P Denton, Peter A Merkel, Daniel E Furst, et al.Breast Cancer Research and Treatment|February 23, 2013
Confirmation of the reduction of hormone replacement therapy-related breast cancer risk for carriers of the HSD17B1_937_G variantOfure Obazee, Christina Justenhoven, Stefan Winter, et al.Pageof 122